Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel

Inclusion Criteria
Patients post-prostatectomy
Baseline testosterone level obtained post prostatectomy prior to step 1 registration
Pathologically (histologically) proven diagnosis of adenocarcinoma of the prostate a
Primary treatment with radical prostatectomy
Exclusion Criteria
Definitive clinical or radiologic evidence of metastatic disease
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years) Ta bladder cancer is not considered invasive
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable if completed more than two years prior to step 1 registration; prior androgen deprivation is allowed
Prostatectomy performed greater than 365 days (1 year) prior to step 1 registration
Severe and/or active co-morbidity defined as follows:
History of inflammatory bowel disease
History of active hepatitis B or C; blood tests are not required to determine if the patient has had hepatitis B or C, unless the patient reports a history of hepatitis
Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
Transmural myocardial infarction within the last 6 months
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of step 1 registration
Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization within 15 days of step 1 registration or precluding study therapy at the time of step 1 registration
Uncontrolled severe illness or medical condition (including uncontrolled diabetes), which in the judgment of the treating physician would make the administration of chemotherapy inadvisable